Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture

被引:80
作者
Archer, RH
Dykes, C
Gerondelis, P
Lloyd, A
Fay, P
Reichman, RC
Bambara, RA
Demeter, LM
机构
[1] Univ Rochester, Infect Dis Unit, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA
[2] Univ Rochester, Dept Microbiol & Immunol, Sch Med & Dent, Rochester, NY 14642 USA
[3] Univ Rochester, Dept Biochem & Biophys, Sch Med & Dent, Rochester, NY 14642 USA
[4] Univ Rochester, Ctr Canc, Sch Med & Dent, Rochester, NY 14642 USA
关键词
D O I
10.1128/JVI.74.18.8390-8401.2000
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Three mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (V106A, V179D, and Y181C), which occur in clinical isolates and confer resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs), were analyzed for RNA- and DNA-dependent DIVA polymerization and RNase H cleavage. All mutants demonstrated processivities of polymerization that were indistinguishable from wild-type enzyme under conditions in which deoxynucleoside triphosphates were not limiting. The V106A reverse transcriptase demonstrated a three- to fourfold slowing of both DNA 3'-end-directed and RNA 5'-end-directed RNase H cleavage relative to both wild-type and V179D enzymes, similar to what was observed for P236L in a previously published study (P. Gerondelis et al., J, Virol, 73:5803-5813, 1999). In contrast, the Y181C reverse transcriptase demonstrated a selective acceleration of the secondary RNase H cleavage step during both modes of RNase H cleavage. The relative replication fitness of these mutants in Ho cells was assessed in parallel infections as well as in growth competition experiments. Of the NNRTI-resistant mutants, V179D was more fit than Y181C, and both of these mutants were more fit than V106A, which demonstrated the greatest reduction in RNase H cleavage. These findings, in combination with results from previous work, suggest that abnormalities in RNase H cleavage are a common characteristic of HIV-1 mutants resistant to NNRTIs and that combined reductions in the rates of DNA 3'-end- and RNA 5'-end-directed cleavages are associated with significant reductions in the replication fitness of HIV-1.
引用
收藏
页码:8390 / 8401
页数:12
相关论文
共 65 条
  • [1] Chimeric HIV-1 and feline immunodeficiency virus reverse transcriptases:: Critical role of the p51 subunit in the structural integrity of heterodimeric lentiviral DNA polymerases
    Amacker, M
    Hübscher, U
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1998, 278 (04) : 757 - 765
  • [2] Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT):: Increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase
    Arion, D
    Kaushik, N
    McCormick, S
    Borkow, G
    Parniak, MA
    [J]. BIOCHEMISTRY, 1998, 37 (45) : 15908 - 15917
  • [3] Arts EJ, 1998, PROG NUCLEIC ACID RE, V58, P339
  • [4] Deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase
    Back, NKT
    Berkhout, B
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) : 2484 - 2491
  • [5] Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme
    Back, NKT
    Nijhuis, M
    Keulen, W
    Boucher, CAB
    Essink, BBO
    vanKuilenburg, ABP
    vanGennip, AH
    Berkhout, B
    [J]. EMBO JOURNAL, 1996, 15 (15) : 4040 - 4049
  • [6] Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial
    Been-Tiktak, AMM
    Boucher, CAB
    Brun-Vezinet, F
    Joly, V
    Mulder, JW
    Jost, J
    Cooper, DA
    Moroni, M
    Gatell, JM
    Staszewski, S
    Colebunders, R
    Stewart, GJ
    Hawkins, DA
    Johnson, MA
    Parkin, JM
    Kennedy, DH
    Hoy, JF
    Borleffs, JCC
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 1999, 11 (01) : 13 - 21
  • [7] MUTATIONAL ANALYSIS OF THE FINGERS AND PALM SUBDOMAINS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) REVERSE-TRANSCRIPTASE
    BOYER, PL
    FERRIS, AL
    CLARK, P
    WHITMER, J
    FRANK, P
    TANTILLO, C
    ARNOLD, E
    HUGHES, SH
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1994, 243 (03) : 472 - 483
  • [8] Boyer PL, 1998, ANTIMICROB AGENTS CH, V42, P447
  • [9] BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
  • [10] Antiretroviral therapy for HIV infection in 1998 - Updated recommendations of the International AIDS Society USA panel
    Carpenter, CCJ
    Fischl, MA
    Hammer, SM
    Hirsch, MS
    Jacobsen, DM
    Katzenstein, DA
    Montaner, JSG
    Richman, DD
    Saag, MS
    Schooley, RT
    Thompson, MA
    Vella, S
    Yeni, PG
    Volberding, PA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (01): : 78 - 86